{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:19:29Z","timestamp":1780582769543,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.atherosclerosis.2025.120634","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:52:52Z","timestamp":1767027172000},"page":"120634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study"],"prefix":"10.1016","volume":"413","author":[{"given":"Shinje","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungdo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-9965","authenticated-orcid":false,"given":"Cheol-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120634_bib1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2014.12.036","article-title":"Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from peripheral academic research consortium (PARC)","volume":"65","author":"Patel","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0002-9149(94)90493-6","article-title":"Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age","volume":"74","author":"Aronow","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib5","first-page":"81","article-title":"Inter-society consensus for the management of peripheral arterial disease","volume":"26","author":"Norgren","year":"2007","journal-title":"Int Angiol"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib6","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.3390\/ijerph19169801","article-title":"Approaches to peripheral artery disease in diabetes: are there any differences?","volume":"19","author":"Achim","year":"2022","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib7","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.jacc.2018.09.078","article-title":"Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial","volume":"72","author":"Low Wang","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM200105243442108","article-title":"Medical treatment of peripheral arterial disease and claudication","volume":"344","author":"Hiatt","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib9","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2014.01.015","article-title":"Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes","volume":"234","author":"Kim","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0049-3848(99)00109-7","article-title":"Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery","volume":"96","author":"Kohda","year":"1999","journal-title":"Thromb Res"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3803\/EnM.2021.1353","article-title":"Comparative study of Ex vivo antiplatelet activity of aspirin and cilostazol in patients with diabetes and high risk of cardiovascular disease","volume":"37","author":"Hong","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120634_bib14","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"Brown","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155327","article-title":"Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels","volume":"137","author":"Kim","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2019.09.012","article-title":"Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review","volume":"293","author":"Agnelli","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib17","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"Brown","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects)","volume":"47","author":"Hiatt","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib19","first-page":"541","article-title":"Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol","volume":"79","author":"Soga","year":"2012","journal-title":"Cathet Cardiovasc Interv"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clinthera.2010.01.007","article-title":"Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients","volume":"32","author":"Ishii","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417439","article-title":"Sex, endothelial cell functions, and peripheral artery disease","volume":"24","author":"Cartland","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11883-025-01330-x","article-title":"Unveiling the sex-based divide: exploring sex differences in peripheral artery disease","volume":"27","author":"Kansul","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvssci.2024.100269","article-title":"Evaluation of sex-based differences in below-the-knee plaque histology in patients who underwent amputation for chronic limbthreatening ischemia","volume":"6","author":"Kansul","year":"2025","journal-title":"JVS-Vascular Sci"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib24","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1002\/ajh.27258","article-title":"The impact of sex on platelet responses to aspirin in patients with peripheral artery disease","volume":"99","author":"Suarez Ferreira","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib25","first-page":"165","article-title":"A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome","volume":"38","author":"Wang","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2011.09.075","article-title":"Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease","volume":"59","author":"Wang","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib27","doi-asserted-by":"crossref","first-page":"H1146","DOI":"10.1152\/ajpheart.00252.2009","article-title":"Intrinsic sexspecific differences in microvascular endothelial cell phosphodiesterases","volume":"298","author":"Wang","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.5551\/jat.63660","article-title":"Sex difference in the impact of dual antiplatelet therapy using cilostazol for secondary stroke prevention: a sub-analysis of CSPS.com","volume":"30","author":"Hoshino","year":"2023","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib29","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/archinte.159.17.2041","article-title":"A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial","volume":"159","author":"Beebe","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jvs.2011.09.004","article-title":"A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication","volume":"55","author":"Brass","year":"2012","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135692","article-title":"Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis","volume":"10","author":"Katsanos","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1526602818771358","article-title":"Sustained effectiveness of cilostazol after endovascular treatment of femoropopliteal lesions: midterm Follow-up from the sufficient treatment of peripheral intervention by cilostazol (STOP-IC) study","volume":"25","author":"Soga","year":"2018","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006564","article-title":"Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery","volume":"11","author":"Miura","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jvs.2024.01.010","article-title":"The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease","volume":"80","author":"Galyfos","year":"2024","journal-title":"J Vasc Surg"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120634_bib35","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3390\/ijms25052593","article-title":"The role of cilostazol, a Phosphodiesterase-3 inhibitor, in the development of atherosclerosis and vascular biology: a review with meta-analysis","volume":"25","author":"Sohn","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0021-9150(98)00147-6","article-title":"Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery","volume":"142","author":"Ishizaka","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib37","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s001250100593","article-title":"Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model","volume":"44","author":"Aoki","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187872","article-title":"Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease","volume":"12","author":"Chancharoenthana","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120634_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1024\/0301-1526\/a001114","article-title":"Cilostazol for peripheral arterial disease - a position paper from the Italian society for angiology and vascular medicine","volume":"53","author":"Martini","year":"2024","journal-title":"Vasa"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.HYP.35.1.237","article-title":"Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21","volume":"35","author":"Hayashi","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib41","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s001250100593","article-title":"Inhibition of neointimal formation after balloon injuryby cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in ratdiabetes model","volume":"44","author":"Aoki","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024646","article-title":"Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in acarotid balloon injury model","volume":"6","author":"Kawabe-Yako","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120634_bib43","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s001250050787","article-title":"Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor","volume":"40","author":"Morishita","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib44","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/eurheartj\/eht149","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I","volume":"34","author":"Paneni","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib45","article-title":"Cilostazol induces eNOS and TM expression via activation with sirtuin 1\/Kr\u00fcppel-like factor 2 pathway in endothelial cells","volume":"22","author":"Wu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pharep.2018.12.005","article-title":"Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model","volume":"71","author":"Cho","year":"2019","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib47","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.atherosclerosis.2006.01.022","article-title":"Activation of endothelial nitric oxide synthase by cilostazol via a cAMP\/protein kinase A- and phosphatidylinositol 3-kinase\/Akt-dependent mechanism","volume":"189","author":"Hashimoto","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044476","article-title":"Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation","volume":"7","author":"Kawanabe","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120634_bib49","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/dom.13667","article-title":"Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study","volume":"21","author":"Lee","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2025.120634_bib50","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1161\/CIRCULATIONAHA.109.892414","article-title":"The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the diabetic atherosclerosis prevention by cilostazol (DAPC) study: a randomized trial","volume":"121","author":"Katakami","year":"2010","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120634_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314957","article-title":"The drug risks of cilostazol: a pharmacovigilance study of FDA adverse event reporting system database","volume":"19","author":"Peng","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4093\/dmj.2016.40.1.79","article-title":"Data analytic process of a nationwide population-based study using national health information database established by national health insurance service","volume":"40","author":"Lee","year":"2016","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.atherosclerosis.2025.120634_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3803\/EnM.2023.102","article-title":"Big data research in the field of endocrine diseases using the Korean national health information database","volume":"38","author":"Cho","year":"2023","journal-title":"Endocrinol Metab (Seoul)"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025015321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025015321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:07:43Z","timestamp":1770286063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025015321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":53,"alternative-id":["S0021915025015321"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120634","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120634"}}